copeptin level
Recently Published Documents


TOTAL DOCUMENTS

50
(FIVE YEARS 26)

H-INDEX

7
(FIVE YEARS 1)

Author(s):  
Onur Sinan Deveci ◽  
Caglar Ozmen ◽  
Muhammet Bugra Karaaslan ◽  
Aziz Inan Celik ◽  
Hatice Rahimova ◽  
...  

Objective Vaso-occlusive crisis (VOC) is a common clinical manifestation of sickle cell anemia (SCA) and is associated with increased proinflammatory mediators. Copeptin is the C-terminal part of the prohormone for pro-vasopressin and seems clinically relevant in various clinical conditions. Right ventricular (RV) dysfunction significantly appears in SCA patients due to pulmonary hypertension. This study aimed to investigate the association of copeptin levels in VOC patients and evaluate RV dysfunction. Materials and Methods A total of 108 patients were enrolled in the study. Twenty-eight SCA patients in steady state (30.2±10.9 years), 25 SCA patients in VOC (36.8±11.8 years), and 55 healthy individuals (31.9±9.4 years) with HbAA genotype were included. Clinical, echocardiographic, and laboratory data were recorded. ELISA was used for the determination of serum levels of copeptin. Results VOC patients had significantly higher copeptin level compared both with controls and SCA subjects in steady-state (22.6±13.0 vs. 11.3±5.7 pmol/l, 22.6±13.0 vs. 12.4±5.8 pmol/l, p=0.009 for both). Additionally, the copeptin level was significantly higher in SCA patients with RV dysfunction than those without RV dysfunction (23.2±12.2 vs. 15.3±9.5 pmol/l, p=0.024). Multiple logistic regression analysis revealed that hs-CRP and copeptin levels were found to be associated with VOC. Conclusion The study showed that copeptin and hs-CRP levels were increased in patients with VOC, and a significant relationship was found between RV dysfunction in VOC patients. As a conclusion copeptin can be used as a potential biomarker in predicting VOC crisis in SCA patients and in early detection of patients with SCA who have the potential to develop RV dysfunction.


Author(s):  
Mohammed I. Oraby ◽  
Rasha H. Soliman ◽  
Rehab M. Abd Elkareem ◽  
Amna I. Mohammed

Abstract Background Copeptin is a new blood biomarker for acute ischemic stroke which emerged to assist clinicians with decision-making. Serum copeptin can accurately reflect vasopressin concentration, which plays a role in aggravation of inflammatory responses, ions and neurotransmitters dysfunctions. The objective of this work was to investigate the relation between copeptin level as a blood biomarker and the short-term prognosis of acute ischemic stroke after 3 months. The current study included 45 patients with first ever acute ischemic stroke and 45 healthy volunteers as a control. Clinical evaluation, CT and MRI of the brain, NIHSS on admission, and mRS after 3 months were done for the patients, and all the patients and control were subjected to assessment of serum level of copeptin by ELISA technique. Results Copeptin level was significantly higher in patients with acute ischemic stroke compared to healthy control subjects (p-value = 0.001). Also, copeptin level was significantly higher in patients with severe stroke (NIHSS > 16) than in those with mild-to-moderate stroke (NIHSS 0–15) at presentation and in patients with unfavorable outcome (mRS 3–6) when compared to patients with favorable outcome (mRS 0–2) (p-value = 0.003 and 0.001, respectively). Copeptin level was significantly lower in patients who received thrombolytic therapy with rTPA (p-value = 0.049). Conclusion Copeptin has an interesting potential as a new prognostic biomarker for patients with acute ischemic stroke as its level was significantly higher in patients with severe stroke and in patients with unfavorable outcome.


2021 ◽  
Vol 23 (Supplement_D) ◽  
Author(s):  
Mahmoud M Hassanein ◽  
Mohammed A Sadaka ◽  
Ahmed Mokhtar ◽  
Nermeen Eldabbah ◽  
Eman Mubarak

Abstract Background Copeptin, C-terminal segment of pro-arginine vasopressin, is expected to be a strong novel biomarker for prognosis in acute heart failure (AHF). Aim Evaluate the prognostic role of copeptin in AHF either de novo or on top of chronic heart failure and its correlation with adverse cardiac events. Methods The study included 45 patients with acute decompensated heart failure (ADHF) to assess the relationship of serum copeptin level on admission and 72 hours after admission with adverse cardiac events (death, re-hospitalization and arrhythmias) in patients hospitalized with ADHF between May 2019 and November 2019 with median follow up period 6 months. Results In this study, 15 patients died, re-admission for heart failure occurred in 22 patients and arrhythmias were documented in 14 patients with atrial fibrillation (n = 9) and ventricular arrhythmias (n = 5). Mortality rate was higher among the elderly, smokers and patients with higher heart rate, lower left ventricular ejection fraction, more frequent arrhythmias, impaired kidney function and higher copeptin level. Furthermore, copeptin level at day 1 with cutoff value of > 2.54 pmol/l predicted mortality with sensitivity of 86.67% and specificity of 53.33% while at day 3 copeptin level with cutoff value > 2.74 pmol/l predicted mortality with sensitivity of 93.33% and specificity of 83.33%. Finally, change in copeptin level between day 1 and day 3 was associated with increased mortality. (p<0.001) Conclusion Serum copeptin is suggested to be a strong biomarker to predict adverse clinical outcomes in patients with acute decompensated heart failure.


2021 ◽  
Author(s):  
Alyaa Ahdy Abdelaziz ◽  
Ahmed Anwer Khattab ◽  
Mohammed Hossam Abdelmaksoud ◽  
Ramy Mohamed Ghazy

Abstract Background: This study aimed to assess the role of copeptin as a diagnostic marker of heart failure (HF) and outcomes. Method: We randomly recruited 76 cardiac patients aged 1 month to 15 years and 65 control healthy children matched in age and sex. Based on plasma copeptin level, the study population were sub-grouped into quartiles (Q). Results: The mean age of cases and control was 40.52 ±34.35 months and 42.43 ±30.42 months respectively. Median copeptin level was higher among patients 16.80 (16.4) compared to control 8.00 (3.0), P<0.01. Copeptin level was not statistically significantly different in-between patients with different etiologies of HF, P =0.515. Total leukocytic count, platelets, serum sodium, inotropic score, and troponin were significantly correlated with copeptin quartile. Three-fourth of dead children were within the Q4, and 12.5 % were within the first one, P=0.214. Around 76.5% of patients who had multiorgan dysfunction were within the Q4 while 5.9% belonged to Q1, P=0.022. Of those who developed sepsis, 82.6% and 4.3% were located within Q4 and Q1, P<0.01. All patients who required mechanical ventilation were within Q4, P= 0.005. Conclusion: Plasma level of copeptin is elevated in pediatric HF regardless its etiology and can be used as a predictor of poor outcomes.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoo Hyung Kim ◽  
Yong Hwy Kim ◽  
Young Soo Je ◽  
Kyoung Ryul Lee ◽  
Hwan Sub Lim ◽  
...  

AbstractCopeptin levels reflect arginine vasopressin (AVP) release from the hypothalamus. Pituitary surgery often impairs AVP release and results in central diabetes insipidus (CDI). Here, we aimed to investigate how serum copeptin level changes 3 months after pituitary surgery and whether it has a diagnostic value for postoperative permanent CDI. Consecutive patients who underwent endoscopic transsphenoidal surgery at a single tertiary hospital were recruited. Serum copeptin levels were measured preoperatively and 3 months postoperatively. Among 88 patients, transient and permanent CDI occurred in 17 (19.3%) and 23 (26.1%), respectively. Three-month postoperative copeptin levels significantly declined from preoperative levels in permanent CDI group (P < 0.001, percentage difference =  − 42.2%) and also in the transient CDI group (P = 0.002, − 27.2%). Three months postoperative copeptin level < 1.9 pmol/L under normal serum sodium levels was the optimal cutoff value for diagnosing permanent CDI with an accuracy of 81.8%, while 3-month postoperative copeptin level ≥ 3.5 pmol/L excluded the CDI with a negative predictive value of 100%. Conclusively, 3 months postoperative copeptin levels significantly decreased from preoperative levels in the transient CDI group as well as the permanent CDI group. Three-month postoperative copeptin levels ≥ 3.5 pmol/L under normal serum sodium levels may be diagnostic for excluding postoperative CDI.


Biomarkers ◽  
2021 ◽  
pp. 1-4
Author(s):  
Lukasz Szarpak ◽  
Aleksandra Gasecka ◽  
Mikołaj Opiełka ◽  
Natasza Gilis-Malinowska ◽  
Krzysztof J. Filipiak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document